LifeStance Health Group (NASDAQ:LFST) Stock Price Expected to Rise, UBS Group Analyst Says

LifeStance Health Group (NASDAQ:LFST) had its price objective upped by analysts at UBS Group from $10.00 to $12.00 in a note issued to investors on Thursday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. UBS Group’s price target indicates a potential upside of 72.79% from the stock’s previous close.

Several other equities analysts have also issued reports on LFST. Zacks Research lowered shares of LifeStance Health Group from a “strong-buy” rating to a “hold” rating in a report on Wednesday, November 5th. Weiss Ratings reissued a “sell (d-)” rating on shares of LifeStance Health Group in a research report on Monday, December 29th. BMO Capital Markets assumed coverage on LifeStance Health Group in a report on Thursday, November 13th. They issued an “outperform” rating and a $8.00 price objective for the company. KeyCorp increased their price target on shares of LifeStance Health Group from $8.00 to $9.00 and gave the stock an “overweight” rating in a report on Thursday. Finally, Barclays initiated coverage on LifeStance Health Group in a research note on Tuesday, December 9th. They issued an “overweight” rating and a $8.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $9.33.

LifeStance Health Group Stock Down 6.3%

LFST stock traded down $0.47 during trading on Thursday, hitting $6.95. 6,496,443 shares of the company’s stock traded hands, compared to its average volume of 1,928,536. The firm has a market capitalization of $2.70 billion, a P/E ratio of -231.57 and a beta of 1.12. LifeStance Health Group has a 1 year low of $3.74 and a 1 year high of $8.30. The company has a quick ratio of 1.58, a current ratio of 1.58 and a debt-to-equity ratio of 0.18. The business has a fifty day simple moving average of $7.12 and a two-hundred day simple moving average of $6.18.

LifeStance Health Group (NASDAQ:LFST) last announced its quarterly earnings results on Wednesday, February 25th. The company reported $0.03 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.02). The company had revenue of $382.20 million during the quarter, compared to analysts’ expectations of $378.51 million. LifeStance Health Group had a negative net margin of 0.67% and a negative return on equity of 0.62%. The company’s revenue was up 17.4% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.01) earnings per share. Sell-side analysts anticipate that LifeStance Health Group will post -0.18 EPS for the current year.

LifeStance Health Group announced that its Board of Directors has initiated a stock repurchase program on Wednesday, February 25th that allows the company to buyback $100.00 million in outstanding shares. This buyback authorization allows the company to reacquire up to 3.6% of its shares through open market purchases. Shares buyback programs are generally an indication that the company’s leadership believes its stock is undervalued.

Insider Transactions at LifeStance Health Group

In other news, Director Robert Bessler sold 119,942 shares of the business’s stock in a transaction that occurred on Friday, December 19th. The stock was sold at an average price of $7.04, for a total transaction of $844,391.68. Following the transaction, the director directly owned 1,318,983 shares in the company, valued at $9,285,640.32. The trade was a 8.34% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Ann Varanakis sold 50,000 shares of the company’s stock in a transaction that occurred on Wednesday, December 17th. The shares were sold at an average price of $6.90, for a total value of $345,000.00. Following the completion of the sale, the insider owned 315,610 shares of the company’s stock, valued at $2,177,709. This trade represents a 13.68% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 270,086 shares of company stock valued at $1,891,264 over the last quarter. Company insiders own 3.20% of the company’s stock.

Institutional Trading of LifeStance Health Group

Hedge funds and other institutional investors have recently modified their holdings of the stock. OLD National Bancorp IN purchased a new stake in shares of LifeStance Health Group in the 3rd quarter valued at approximately $508,000. Squarepoint Ops LLC boosted its position in shares of LifeStance Health Group by 259.1% during the 2nd quarter. Squarepoint Ops LLC now owns 1,360,054 shares of the company’s stock worth $7,031,000 after purchasing an additional 981,349 shares during the period. AXQ Capital LP acquired a new stake in LifeStance Health Group in the 2nd quarter valued at approximately $343,000. Loomis Sayles & Co. L P raised its position in LifeStance Health Group by 4.5% in the second quarter. Loomis Sayles & Co. L P now owns 2,343,028 shares of the company’s stock valued at $12,113,000 after purchasing an additional 100,657 shares during the period. Finally, Alberta Investment Management Corp purchased a new stake in LifeStance Health Group in the second quarter valued at approximately $607,000. 85.50% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about LifeStance Health Group

Here are the key news stories impacting LifeStance Health Group this week:

• Positive Sentiment: Company issued 2026 targets and approved a $100M buyback, signaling confidence in cash flow and growth; management is also advancing AI/EHR initiatives that it says should drive productivity and scale. Lifestance outlines $1.615B–$1.655B 2026 revenue target while advancing AI, EHR initiatives and $100M buyback
• Positive Sentiment: Q4 revenue and key operating metrics were strong: revenue $382.2M (+17% YoY), adjusted EBITDA and net income turned positive, clinician base and visit volumes grew — supporting the company’s optimistic FY2026 revenue/EBITDA guidance. LifeStance Reports Fourth Quarter and Full Year 2025 Results
• Positive Sentiment: KeyCorp raised its price target from $8 to $9 and put an overweight rating on LFST, which provides some analyst support for upside from current levels. KeyCorp raises price target
• Neutral Sentiment: Earnings/transcript publications are available (conference call commentary and Q&A may contain additional execution details / cadence for 2026). Investors should review the call for color on margins, clinician productivity, and cadence of buybacks. Q4 2025 Earnings Call Transcript
• Negative Sentiment: Reported EPS of ~$0.03 missed consensus (~$0.05), creating short-term disappointment despite the revenue beat — a common catalyst for intraday selling. Q4 earnings miss detail
• Negative Sentiment: Selling stockholders launched a secondary offering of 25M shares (company not raising proceeds) — this increases potential share supply and creates near-term selling pressure/overhang. Secondary public offering announcement
• Negative Sentiment: Recent reports highlight material insider selling and chunky institutional moves (some firms reducing exposure), which can amplify downside when combined with the offering and an EPS miss. QuiverQuant summary (insider & institutional activity)

LifeStance Health Group Company Profile

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.